Clinical trialPhase 2Active not recruiting
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology
- Outcome
- Ongoing. Results posted; single-arm, no comparison
- Phase
- Phase 2
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 30 December 2020
- Listed end
- 14 July 2026
- Enrollment
- 102 participants
- Sites
- 30
- Primary outcomes
- Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR)
- Sponsor type
- Industry
- Results posted
- 15 February 2024
- Last update
- 23 March 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 23 March 2026
- ORR
- Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR)T-DXd: 29.4 (20.8 to 39.3), n = 102Values: percentage of participants, 95% Confidence IntervalTime frame: Tumor scans performed at screening,then every 6 weeks (q6w) +/- 1 week relative to date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)No analysis posted for this outcome (outcome 1)
- Participants
- Trastuzumab Deruxtecan (T-DXd): 102 started, 33 completed
- Serious adverse events
- T-DXd: 36 of 102Participants with at least one serious adverse event, of those at risk, as posted
- Reported in
- Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international,… DOI 10.1016/s1470-2045(24)00140-2↗ Linked as this trial’s results paper. The numbers above are the registry’s, not the paper’s.
10 secondary outcomes, the first 8 shown
- Duration of Response (DoR) as Per RECIST v1.1 Using ICR and Investigator Assessment
- DoR by ICR: T-DXd NA (6.8 to NA), n=30 [median months, Inter-Quartile Range] (first of 2 rows)
- DCR · Disease Control Rate (DCR) as Per RECIST v1.1 Using ICR and Investigator Assessment
- DCR at 6 weeks by ICR: T-DXd 75.5 (66.0 to 83.5), n=102 [percentage of participants, 95% Confidence Interval] (first of 4 rows)
- PFS · PFS as Per RECIST v1.1 Using ICR and Investigator Assessment
- PFS by ICR: T-DXd 5.4 (2.7 to 7.1), n=102 [median months, 95% Confidence Interval] (first of 2 rows)
- Percentage of Participants Alive and Progression-Free at 6 and 12 Months as Per RECIST v1…
- PFS rate at 6 months by ICR: T-DXd 41.4 (30.8 to 51.6), n=102 [percentage of participants, 95% Confidence Interval] (first of 4 rows)
- Confirmed ORR as Per RECIST v1.1 Using Investigator Assessment
- T-DXd 32.4 (23.4 to 42.3), n=102 [percentage of participants, 95% Confidence Interval]
- OS · Overall Survival (OS)
- T-DXd 10.9 (8.3 to 14.9), n=102 [median months, 95% Confidence Interval]
- Percentage of Participants Alive at 6 and 12 Months
- Survival rate at 6 months: T-DXd 67.6 (57.4 to 75.9), n=102 [percentage of participants, 95% Confidence Interval] (first of 2 rows)
- Serum Concentrations of T-DXd and Total Anti-HER2 Antibody
- T-DXd: Cycle 1: Pre-infusion: T-DXd NA (NA), n=1 [mean microgram/milliliter (mL), Standard Deviation] (first of 14 rows)
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are patients who have progressed following prior treatment or who have no satisfactory alternative treatment options, including approved second line therapies in the specific tumor type. Pre-specified HER2 mutations will be locally assessed using NGS tests or alternative methods. Prior HER2 targeting therapy is permitted.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR) [Tumor scans performed at screening,then every 6 weeks (q6w) +/- 1 week relative to date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)]. Number, percentage of participants (95% Confidence Interval). T-DXd (n=102): 29.4 (20.8 to 39.3).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Duration of Response (DoR) as Per RECIST v1.1 Using ICR and Investigator Assessment [Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)]. Median, months (Inter-Quartile Range). DoR by ICR: T-DXd (n=102): NA (6.8 to NA) [NA indicates that median and upper limit of confidence interval (CI) were not estimable due to insufficient number of participants with events at study closure.]. DoR by Investigator assessment: T-DXd (n=102): 11.0 (6.9 to 18.1).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Disease Control Rate (DCR) as Per RECIST v1.1 Using ICR and Investigator Assessment [Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)]. Number, percentage of participants (95% Confidence Interval). DCR at 6 weeks by ICR: T-DXd (n=102): 75.5 (66.0 to 83.5). DCR at 6 weeks by Investigator assessment: T-DXd (n=102): 70.6 (60.7 to 79.2). DCR at 12 weeks by ICR: T-DXd (n=102): 53.9 (43.8 to 63.8). DCR at 12 weeks by Investigator assessment: T-DXd (n=102): 55.9 (45.7 to 65.7).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
PFS as Per RECIST v1.1 Using ICR and Investigator Assessment [Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)]. Median, months (95% Confidence Interval). PFS by ICR: T-DXd (n=102): 5.4 (2.7 to 7.1). PFS by Investigator assessment: T-DXd (n=102): 4.4 (2.8 to 5.6).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Percentage of Participants Alive and Progression-Free at 6 and 12 Months as Per RECIST v1.1 Using ICR and Investigator Assessment [At Months 6 and 12]. Number, percentage of participants (95% Confidence Interval). PFS rate at 6 months by ICR: T-DXd (n=102): 41.4 (30.8 to 51.6). PFS rate at 6 months by Investigator assessment: T-DXd (n=102): 37.7 (28.1 to 47.2). PFS rate at 12 months by ICR: T-DXd (n=102): 30.9 (20.6 to 41.8). PFS rate at 12 months by Investigator assessment: T-DXd (n=102): 26.5 (17.2 to 36.7).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Confirmed ORR as Per RECIST v1.1 Using Investigator Assessment [Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)]. Number, percentage of participants (95% Confidence Interval). T-DXd (n=102): 32.4 (23.4 to 42.3).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival (OS) [From the date of first treatment administration up to death, approximately 24 months]. Median, months (95% Confidence Interval). T-DXd (n=102): 10.9 (8.3 to 14.9).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Percentage of Participants Alive at 6 and 12 Months [At Months 6 and 12]. Number, percentage of participants (95% Confidence Interval). Survival rate at 6 months: T-DXd (n=102): 67.6 (57.4 to 75.9). Survival rate at 12 months: T-DXd (n=102): 46.3 (35.7 to 56.3).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Serum Concentrations of T-DXd and Total Anti-HER2 Antibody [Pre-infusion and 15 minutes post-infusion in Cycles 1, 2 and 4 and 5 hours post-infusion in Cycle 1 (each cycle 21 days)]. Mean, microgram/milliliter (mL) (Standard Deviation). T-DXd: Cycle 1: Pre-infusion: T-DXd (n=100): NA (NA) [Mean was \<lower limit of quantification (LLOQ). LLOQ was 400 nanogram (ng)/mL.]. T-DXd: Cycle 1: 15 minutes post-infusion: T-DXd (n=100): 116.5 (50.8). T-DXd: Cycle 1: 5 hours post-infusion: T-DXd (n=100): 115.4 (30.5). T-DXd: Cycle 2: Pre-infusion: T-DXd (n=100): 11.2 (74.1). T-DXd: Cycle 2: 15 minutes post-infusion: T-DXd (n=100): 132.2 (101.5). T-DXd: Cycle 4: Pre-infusion: T-DXd (n=100): 7.7 (9.1). T-DXd: Cycle 4: 15 minutes post-infusion: T-DXd (n=100): 121.7 (40.1). Total anti-HER2 antibody: Cycle 1: Pre-infusion: T-DXd (n=100): NA (NA) [Mean was \<LLOQ. LLOQ was 400 ng/mL.]. Total anti-HER2 antibody: Cycle 1: 15 minutes post-infusion: T-DXd (n=100): 123.8 (52.8). Total anti-HER2 antibody: Cycle 1: 5 hours post-infusion: T-DXd (n=100): 122.1 (42.1). Total anti-HER2 antibody: Cycle 2: Pre-infusion: T-DXd (n=100): 6.2 (12.4). Total anti-HER2 antibody: Cycle 2: 15 minutes post-infusion: T-DXd (n=100): 144.4 (115.4). Total anti-HER2 antibody: Cycle 4: Pre-infusion: T-DXd (n=100): 9.9 (5.7). Total anti-HER2 antibody: Cycle 4: 15 minutes post-infusion: T-DXd (n=100): 122.1 (37.3).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Serum Concentrations of Deruxtecan (MAAA-1181a) [Pre-infusion and 15 minutes post-infusion in Cycles 1, 2 and 4 and 5 hours post-infusion in Cycle 1 (each cycle 21 days)]. Mean, ng/mL (Standard Deviation). MAAA-1181a: Cycle 1: 15 minutes post-infusion: T-DXd (n=100): 4.7 (2.9). MAAA-1181a: Cycle 1: 5 hours post-infusion: T-DXd (n=100): 10.5 (5.1). MAAA-1181a: Cycle 2: Pre-infusion: T-DXd (n=100): 0.2 (0.1). MAAA-1181a: Cycle 2: 15 minutes post-infusion: T-DXd (n=100): 2.2 (1.5). MAAA-1181a: Cycle 4: Pre-infusion: T-DXd (n=100): 0.3 (0.2). MAAA-1181a: Cycle 4: 15 minutes post-infusion: T-DXd (n=100): 1.5 (0.9).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Percentage of Participants With Anti-Drug Antibodies (ADA) to T-DXd [Up to approximately 24 months]. Number, percentage of participants. ADA positive at any visit (ADA prevalence): T-DXd (n=96): 2.1. ADA incidence: T-DXd (n=96): 0. Treatment-emergent ADA positive: T-DXd (n=96): 0. Treatment-boosted ADA positive: T-DXd (n=96): 0. Persistently positive ADA: T-DXd (n=96): 0. Transiently positive ADA: T-DXd (n=96): 0.
Papers 2
- Registry-listed results paperTrastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01… DOI 10.1016/s1470-2045(24)00140-2↗
- Builds on itNeratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes an… DOI 10.1016/j.annonc.2023.08.003↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.